These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Neonatal candidiasis and liposomal amphotericin B treatment: our experience]. Carrasco Sánchez P; Castillo Montero ML; Bejarano Palma A; López Sanz A; Santano Gallinato M; Sáenz Reguera C; Durán de Vargas L; González-Meneses A An Esp Pediatr; 1999 Sep; 51(3):273-80. PubMed ID: 10575751 [TBL] [Abstract][Full Text] [Related]
23. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Juul SE; McPherson RJ; Bauer LA; Ledbetter KJ; Gleason CA; Mayock DE Pediatrics; 2008 Aug; 122(2):383-91. PubMed ID: 18676557 [TBL] [Abstract][Full Text] [Related]
24. Severe intraventricular hemorrhage in preterm infants: comparison of risk factors and short-term neonatal morbidities between grade 3 and grade 4 intraventricular hemorrhage. Sarkar S; Bhagat I; Dechert R; Schumacher RE; Donn SM Am J Perinatol; 2009 Jun; 26(6):419-24. PubMed ID: 19267317 [TBL] [Abstract][Full Text] [Related]
25. Current and future chemotherapy of central nervous system fungal infections. Utz JP Adv Neurol; 1974; 6():127-32. PubMed ID: 4480013 [No Abstract] [Full Text] [Related]
26. Early neutropenia is not associated with an increased rate of nosocomial infection in very low-birth-weight infants. Teng RJ; Wu TJ; Garrison RD; Sharma R; Hudak ML J Perinatol; 2009 Mar; 29(3):219-24. PubMed ID: 19078971 [TBL] [Abstract][Full Text] [Related]
27. Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants. Jaillard S; Larrue B; Rakza T; Magnenant E; Warembourg H; Storme L Ann Thorac Surg; 2006 Jan; 81(1):231-4. PubMed ID: 16368371 [TBL] [Abstract][Full Text] [Related]
28. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Weisman L Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450 [TBL] [Abstract][Full Text] [Related]
35. Liposomal amphotericin B treatment for neonatal fungal infections. Scarcella A; Pasquariello MB; Giugliano B; Vendemmia M; de Lucia A Pediatr Infect Dis J; 1998 Feb; 17(2):146-8. PubMed ID: 9493812 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. Baley JE; Meyers C; Kliegman RM; Jacobs MR; Blumer JL J Pediatr; 1990 May; 116(5):791-7. PubMed ID: 2329429 [TBL] [Abstract][Full Text] [Related]
37. Systemic fungal infection in very low-birth-weight infants. Wang LW; Lin CH; Liu CC; Lin YJ Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1996; 37(4):272-7. PubMed ID: 8854349 [TBL] [Abstract][Full Text] [Related]
38. [Clinical pharmacology of antifungal agents in deep mycoses]. Azanza Perea JR; Honorato Pérez J; Cuena Boy R Rev Med Univ Navarra; 1983 Sep; 27(3):19-24. PubMed ID: 6669848 [No Abstract] [Full Text] [Related]
39. Increased level/dose ratio of amphotericin-B in premature infants with renal failure. Higuchi R; Kusumoto S; Ban H; Iwahashi S; Kobayashi M; Sumiyama K; Koike M Acta Paediatr Jpn; 1993 Jun; 35(3):238-42. PubMed ID: 8351992 [TBL] [Abstract][Full Text] [Related]
40. Renal stone formation following medical treatment of renal candidiasis. Cramer BC; Ozere R; Andrews W Pediatr Radiol; 1990; 21(1):43-4. PubMed ID: 2287538 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]